859 related articles for article (PubMed ID: 21971460)
1. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
[TBL] [Abstract][Full Text] [Related]
2. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease.
Gainotti G; Quaranta D; Vita MG; Marra C
J Alzheimers Dis; 2014; 38(3):481-95. PubMed ID: 24002185
[TBL] [Abstract][Full Text] [Related]
4. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
6. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
7. A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease.
Demirtaş M; Falcon C; Tucholka A; Gispert JD; Molinuevo JL; Deco G
Neuroimage Clin; 2017; 16():343-354. PubMed ID: 28861336
[TBL] [Abstract][Full Text] [Related]
8. Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau.
McCollum LE; Das SR; Xie L; de Flores R; Wang J; Xie SX; Wisse LEM; Yushkevich PA; Wolk DA;
Neuroimage Clin; 2021; 31():102717. PubMed ID: 34119903
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.
Skouras S; Falcon C; Tucholka A; Rami L; Sanchez-Valle R; Lladó A; Gispert JD; Molinuevo JL
Neuroimage Clin; 2019; 22():101777. PubMed ID: 30913531
[TBL] [Abstract][Full Text] [Related]
10. Multimodal Magnetic Resonance Imaging in Alzheimer's Disease Patients at Prodromal Stage.
Eustache P; Nemmi F; Saint-Aubert L; Pariente J; Péran P
J Alzheimers Dis; 2016; 50(4):1035-50. PubMed ID: 26836151
[TBL] [Abstract][Full Text] [Related]
11. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
12. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
[TBL] [Abstract][Full Text] [Related]
13. CSF and brain structural imaging markers of the Alzheimer's pathological cascade.
Yang X; Tan MZ; Qiu A
PLoS One; 2012; 7(12):e47406. PubMed ID: 23284610
[TBL] [Abstract][Full Text] [Related]
14. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
15. A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive Impairment.
Terry DP; Sabatinelli D; Puente AN; Lazar NA; Miller LS
J Neuroimaging; 2015; 25(6):849-60. PubMed ID: 26076800
[TBL] [Abstract][Full Text] [Related]
16. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
17. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
[TBL] [Abstract][Full Text] [Related]
20. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
